

Morten HÃ¸yer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1729209/publications.pdf>

Version: 2024-02-01

158
papers

8,285
citations

61977

43
h-index

51602

86
g-index

158
all docs

158
docs citations

158
times ranked

7917
citing authors

#	ARTICLE	IF	CITATIONS
1	Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. <i>Lancet, The</i> , 2009, 373, 301-308.	13.7	789
2	Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 3290-3296.	1.6	780
3	Phase II study on stereotactic body radiotherapy of colorectal metastases. <i>Acta Oncologica</i> , 2006, 45, 823-830.	1.8	379
4	Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. <i>Radiotherapy and Oncology</i> , 2020, 148, 157-166.	0.6	352
5	Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. <i>Radiotherapy and Oncology</i> , 2005, 76, 48-53.	0.6	323
6	Macrophage Markers in Serum and Tumor Have Prognostic Impact in American Joint Committee on Cancer Stage I/II Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3330-3337.	1.6	255
7	ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 11-17.	0.6	230
8	Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. <i>Acta Oncologica</i> , 2006, 45, 787-795.	1.8	220
9	Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. <i>Cancer</i> , 2012, 118, 2476-2485.	4.1	219
10	Radiotherapy for Liver Metastases: A Review of Evidence. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1047-1057.	0.8	172
11	Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. <i>Cancer Treatment Reviews</i> , 2017, 53, 25-37.	7.7	169
12	Stereotactic body radiotherapy for unresectable cholangiocarcinoma. <i>Radiotherapy and Oncology</i> , 2010, 94, 47-52.	0.6	159
13	The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. <i>Radiotherapy and Oncology</i> , 1999, 50, 13-23.	0.6	139
14	The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996, 35, 701-708.	0.8	138
15	Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. <i>Radiotherapy and Oncology</i> , 1997, 43, 47-51.	0.6	133
16	Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer – A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. <i>Radiotherapy and Oncology</i> , 2008, 88, 359-367.	0.6	129
17	Deformable image registration for contour propagation from CT to cone-beam CT scans in radiotherapy of prostate cancer. <i>Acta Oncologica</i> , 2011, 50, 918-925.	1.8	118
18	Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus. <i>Radiotherapy and Oncology</i> , 2018, 128, 26-36.	0.6	112

#	ARTICLE	IF	CITATIONS
19	Impact of changes in bladder and rectal filling volume on organ motion and dose distribution of the bladder in radiotherapy for urinary bladder cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 436-444.	0.8	103
20	Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. <i>Radiotherapy and Oncology</i> , 2015, 114, 155-160.	0.6	100
21	Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2009, 93, 402-407.	0.6	98
22	Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. <i>Radiotherapy and Oncology</i> , 1993, 27, 131-139.	0.6	83
23	Propagation of target and organ at risk contours in radiotherapy of prostate cancer using deformable image registration. <i>Acta Oncologica</i> , 2010, 49, 1023-1032.	1.8	83
24	Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7. <i>European Urology</i> , 2016, 70, 684-691.	1.9	71
25	Adaptive plan selection vs. re-optimisation in radiotherapy for bladder cancer: A dose accumulation comparison. <i>Radiotherapy and Oncology</i> , 2013, 109, 457-462.	0.6	68
26	Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT – the Nordic experience. <i>Acta Oncologica</i> , 2015, 54, 1096-1104.	1.8	66
27	Three-dimensional, Time-Resolved, Intrafraction Motion Monitoring Throughout Stereotactic Liver Radiation Therapy on a Conventional Linear Accelerator. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 190-197.	0.8	65
28	Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer. <i>Radiotherapy and Oncology</i> , 2004, 72, 139-145.	0.6	63
29	A comparison of three different adaptive strategies in image-guided radiotherapy of bladder cancer. <i>Acta Oncologica</i> , 2010, 49, 1069-1076.	1.8	59
30	Normal tissue sparing in a phase II trial on daily adaptive plan selection in radiotherapy for urinary bladder cancer. <i>Acta Oncologica</i> , 2014, 53, 997-1004.	1.8	59
31	Dose-volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy. <i>Radiotherapy and Oncology</i> , 2005, 74, 203-210.	0.6	58
32	Inter- and intrafractional localisation errors in cone-beam CT guided stereotactic radiation therapy of tumours in the liver and lung. <i>Acta Oncologica</i> , 2010, 49, 1177-1183.	1.8	58
33	Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. <i>Radiotherapy and Oncology</i> , 2017, 123, 182-188.	0.6	55
34	Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381879021.	1.9	53
35	Phase II Study of Vinorelbine in the Treatment of Platinum-Resistant Ovarian Carcinoma. <i>Gynecologic Oncology</i> , 2001, 81, 58-62.	1.4	52
36	Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours. <i>Acta Oncologica</i> , 2011, 50, 823-828.	1.8	52

#	ARTICLE	IF	CITATIONS
37	The potential of MRI-guided online adaptive re-optimisation in radiotherapy of urinary bladder cancer. <i>Radiotherapy and Oncology</i> , 2016, 118, 154-159.	0.6	49
38	Variations in magnitude and directionality of respiratory target motion throughout full treatment courses of stereotactic body radiotherapy for tumors in the liver. <i>Acta Oncologica</i> , 2013, 52, 1437-1444.	1.8	47
39	Kilovoltage intrafraction motion monitoring and target dose reconstruction for stereotactic volumetric modulated arc therapy of tumors in the liver. <i>Radiotherapy and Oncology</i> , 2014, 111, 424-430.	0.6	47
40	Nonsurgical Salvage Local Therapies for Radiorecurrent Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2020, 3, 183-197.	5.4	46
41	A study of image-guided radiotherapy of bladder cancer based on lipiodol injection in the bladder wall. <i>Acta Oncologica</i> , 2010, 49, 1109-1115.	1.8	45
42	Residual set-up errors and margins in on-line image-guided prostate localization in radiotherapy. <i>Radiotherapy and Oncology</i> , 2007, 85, 201-206.	0.6	44
43	Degradation of target coverage due to inter-fraction motion during intensity-modulated proton therapy of prostate and elective targets. <i>Acta Oncologica</i> , 2013, 52, 521-527.	1.8	43
44	Respiratory gating based on internal electromagnetic motion monitoring during stereotactic liver radiation therapy: First results. <i>Acta Oncologica</i> , 2015, 54, 1445-1452.	1.8	43
45	A Prospective Cohort Study of Gated Stereotactic Liver Radiation Therapy Using Continuous Internal Electromagnetic Motion Monitoring. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 366-375.	0.8	43
46	The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy. <i>Acta Oncologica</i> , 2009, 48, 238-244.	1.8	42
47	Time-Resolved Intrafraction Target Translations and Rotations During Stereotactic Liver Radiation Therapy: Implications for Marker-based Localization Accuracy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 802-809.	0.8	42
48	Optimization of a flow cytometric method for the simultaneous measurement of cell surface antigen, DNA content, and in vitro BrdUrd incorporation into normal and malignant hematopoietic cells. , 1998, 32, 28-36.		41
49	Faecal incontinence following radiotherapy for prostate cancer: A systematic review. <i>Radiotherapy and Oncology</i> , 2011, 98, 145-153.	0.6	41
50	Robust automatic segmentation of multiple implanted cylindrical gold fiducial markers in cone-beam CT projections. <i>Medical Physics</i> , 2011, 38, 6351-6361.	3.0	39
51	Does the uncertainty in relative biological effectiveness affect patient treatment in proton therapy?. <i>Radiotherapy and Oncology</i> , 2021, 163, 177-184.	0.6	38
52	Aggravation of dyspnea in stage I non-small cell lung cancer patients following stereotactic body radiotherapy: Is there a dose-volume dependency?. <i>Acta Oncologica</i> , 2006, 45, 818-822.	1.8	36
53	An international survey on liver metastases radiotherapy. <i>Acta Oncologica</i> , 2012, 51, 568-574.	1.8	35
54	Internal movement, set-up accuracy and margins for stereotactic body radiotherapy using a stereotactic body frame. <i>Acta Oncologica</i> , 2006, 45, 948-952.	1.8	34

#	ARTICLE	IF	CITATIONS
55	A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II). <i>BMC Cancer</i> , 2016, 16, 183.	2.6	34
56	Image-guided adaptive radiotherapy – integration of biology and technology to improve clinical outcome. <i>Acta Oncologica</i> , 2008, 47, 1182-1185.	1.8	32
57	Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer. <i>Acta Oncologica</i> , 2015, 54, 1326-1334.	1.8	32
58	Cognitive impairment following radiation to hippocampus and other brain structures in adults with primary brain tumours. <i>Radiotherapy and Oncology</i> , 2020, 148, 1-7.	0.6	32
59	Lack of predictive value of potential doubling time and iododeoxyuridine labelling index in radiotherapy of squamous cell carcinoma of the head and neck. <i>Radiotherapy and Oncology</i> , 1998, 46, 147-155.	0.6	31
60	NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction. <i>Acta Oncologica</i> , 2011, 50, 518-527.	1.8	31
61	A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer. <i>Acta Oncologica</i> , 2014, 53, 1321-1328.	1.8	31
62	Long-term cognitive dysfunction after radiation therapy for primary brain tumors. <i>Acta Oncologica</i> , 2019, 58, 745-752.	1.8	29
63	Imaging of normal lung, liver and parotid gland function for radiotherapy. <i>Acta Oncologica</i> , 2010, 49, 997-1011.	1.8	28
64	Half body irradiation of patients with multiple bone metastases: A phase II trial. <i>Acta Oncologica</i> , 2009, 48, 556-561.	1.8	27
65	DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure. , 1998, 36, 244-249.		26
66	On-Line Use of Three-Dimensional Marker Trajectory Estimation From Cone-Beam Computed Tomography Projections for Precise Setup in Radiotherapy for Targets With Respiratory Motion. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e145-e151.	0.8	26
67	Evaluation of an application for intensity-based deformable image registration and dose accumulation in radiotherapy. <i>Acta Oncologica</i> , 2014, 53, 1329-1336.	1.8	26
68	Intra-fractional bladder motion and margins in adaptive radiotherapy for urinary bladder cancer. <i>Acta Oncologica</i> , 2015, 54, 1461-1466.	1.8	26
69	The usability of a 15-gene hypoxia classifier as a universal hypoxia profile in various cancer cell types. <i>Radiotherapy and Oncology</i> , 2015, 116, 346-351.	0.6	26
70	The normal tissue sparing potential of adaptive strategies in radiotherapy of bladder cancer. <i>Acta Oncologica</i> , 2008, 47, 1382-1389.	1.8	24
71	Time-resolved dose distributions to moving targets during volumetric modulated arc therapy with and without dynamic MLC tracking. <i>Medical Physics</i> , 2013, 40, 111723.	3.0	24
72	Fiducial marker guided stereotactic liver radiotherapy: Is a time delay between marker implantation and planning CT needed?. <i>Radiotherapy and Oncology</i> , 2016, 121, 75-78.	0.6	24

#	ARTICLE	IF	CITATIONS
73	Biology-guided adaptive radiotherapy (BiGART) – more than a vision?. <i>Acta Oncologica</i> , 2013, 52, 1243-1247.	1.8	23
74	Development and validation of a scoring system for late anorectal side-effects in patients treated with radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2014, 111, 94-99.	0.6	23
75	Urinary bladder dose–response relationships for patient-reported genitourinary morbidity domains following prostate cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 119, 117-122.	0.6	23
76	Spatial rectal dose/volume metrics predict patient-reported gastro-intestinal symptoms after radiotherapy for prostate cancer. <i>Acta Oncologica</i> , 2017, 56, 1507-1513.	1.8	23
77	Evaluation of adaptive radiotherapy of bladder cancer by image-based tumour control probability modelling. <i>Acta Oncologica</i> , 2010, 49, 1045-1051.	1.8	22
78	Validity of the Danish National Registry of Patients for chemotherapy reporting among colorectal cancer patients is high. <i>Clinical Epidemiology</i> , 2013, 5, 327.	3.0	22
79	Fast motion-including dose error reconstruction for VMAT with and without MLC tracking. <i>Physics in Medicine and Biology</i> , 2014, 59, 7279-7296.	3.0	22
80	First clinical real-time motion-including tumor dose reconstruction during radiotherapy delivery. <i>Radiotherapy and Oncology</i> , 2019, 139, 66-71.	0.6	21
81	The emerging evidence for Stereotactic Body Radiotherapy. <i>Acta Oncologica</i> , 2006, 45, 771-774.	1.8	20
82	FDG-PET Improves Management of Patients with Colorectal Liver Metastases Allocated for Local Treatment: A Consecutive Prospective Study. <i>Scandinavian Journal of Surgery</i> , 2007, 96, 209-213.	2.6	20
83	Automatic online and real-time tumour motion monitoring during stereotactic liver treatments on a conventional linac by combined optical and sparse monoscopic imaging with kilovoltage x-rays (COSMIK). <i>Physics in Medicine and Biology</i> , 2018, 63, 055012.	3.0	20
84	Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer. <i>Acta Oncologica</i> , 2004, 43, 749-757.	1.8	19
85	Radical radiotherapy for urinary bladder cancer: treatment outcomes. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 269-279.	2.4	19
86	Patient specific outcomes of charged particle therapy for hepatocellular carcinoma – A systematic review and quantitative analysis. <i>Radiotherapy and Oncology</i> , 2019, 132, 127-134.	0.6	19
87	Comparison of two dose calculation methods applied to extracranial stereotactic radiotherapy treatment planning. <i>Radiotherapy and Oncology</i> , 2005, 77, 96-98.	0.6	18
88	A method to individualize adaptive planning target volumes for deformable targets. <i>Physics in Medicine and Biology</i> , 2009, 54, 7121-7133.	3.0	18
89	Clinical validation of a 4D-CT based method for lung ventilation measurement in phantoms and patients. <i>Acta Oncologica</i> , 2011, 50, 897-907.	1.8	18
90	Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row. <i>World Journal of Urology</i> , 2019, 37, 2607-2613.	2.2	18

#	ARTICLE	IF	CITATIONS
91	Influence of sampling time on assessment of potential doubling time. <i>Cytometry</i> , 1994, 16, 144-151.	1.8	17
92	MIB1 expression and iododeoxyuridine labelling in soft tissue sarcomas: an immunohistochemical study including correlations with p53, bcl2 and histological characteristics. <i>Histopathology</i> , 1996, 28, 437-444.	2.9	17
93	Interaction between potential doubling time and TP53 mutation: predicting radiotherapy outcome in squamous cell carcinoma of the head and neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 519-525.	0.8	17
94	Biology-guided adaptive radiation therapy – presence or future?. <i>Acta Oncologica</i> , 2010, 49, 884-887.	1.8	17
95	Salvage radiation therapy following radical prostatectomy. A national Danish study. <i>Acta Oncologica</i> , 2016, 55, 598-603.	1.8	17
96	Cone beam CT-based set-up strategies with and without rotational correction for stereotactic body radiation therapy in the liver. <i>Acta Oncologica</i> , 2017, 56, 860-866.	1.8	17
97	Metastasis directed therapy for liver and lung metastases from colorectal cancer – A population-based study. <i>International Journal of Cancer</i> , 2018, 143, 3218-3226.	5.1	17
98	Intrafraction changes of prostate position and geometrical errors studied by continuous electronic portal imaging. <i>Acta Oncologica</i> , 2008, 47, 1351-1357.	1.8	16
99	Metabolic liver function after stereotactic body radiation therapy for hepatocellular carcinoma. <i>Acta Oncologica</i> , 2016, 55, 886-891.	1.8	16
100	Geometric and dosimetric comparison of four intrafraction motion adaptation strategies for stereotactic liver radiotherapy. <i>Physics in Medicine and Biology</i> , 2018, 63, 145010.	3.0	16
101	Temporary sacral nerve stimulation for faecal incontinence following pelvic radiotherapy. <i>Radiotherapy and Oncology</i> , 2010, 97, 108-112.	0.6	15
102	An adaptive radiotherapy planning strategy for bladder cancer using deformation vector fields. <i>Radiotherapy and Oncology</i> , 2014, 112, 371-375.	0.6	15
103	Temporal lobe sparing radiotherapy with photons or protons for cognitive function preservation in paediatric craniopharyngioma. <i>Radiotherapy and Oncology</i> , 2020, 142, 140-146.	0.6	15
104	Re-irradiation with stereotactic body radiation therapy (SBRT). <i>Chinese Clinical Oncology</i> , 2017, 6, S15-S15.	1.2	15
105	Inter-institutional analysis demonstrates the importance of lower than previously anticipated dose regions to prevent late rectal bleeding following prostate radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 127, 88-95.	0.6	14
106	Radiation therapy for liver metastases. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 97-102.	1.3	13
107	Time-resolved dose reconstruction by motion encoding of volumetric modulated arc therapy fields delivered with and without dynamic multi-leaf collimator tracking. <i>Acta Oncologica</i> , 2013, 52, 1497-1503.	1.8	13
108	Quality of venous thromboembolism diagnoses among prostate cancer patients in the Danish National Registry of Patients. <i>Clinical Epidemiology</i> , 2014, 6, 351.	3.0	13

#	ARTICLE	IF	CITATIONS
109	Radiation doses to brain substructures associated with cognition in radiotherapy of pediatric brain tumors. <i>Acta Oncologica</i> , 2019, 58, 1457-1462.	1.8	13
110	Improved accuracy and outcome in radiotherapy of lung cancer. <i>Radiotherapy and Oncology</i> , 2008, 87, 1-2.	0.6	12
111	Particle Therapy – A next logical step in the improvement of radiotherapy. <i>Acta Oncologica</i> , 2011, 50, 741-744.	1.8	12
112	Stereotactic body radiation therapy – A discipline with Nordic origin and profile. <i>Acta Oncologica</i> , 2012, 51, 564-567.	1.8	12
113	Survival and prognostic factors in patients treated with stereotactic radiotherapy for brain metastases. <i>Acta Oncologica</i> , 2015, 54, 107-114.	1.8	12
114	Accuracy of image-guided radiotherapy of prostate cancer based on the BeamCath® urethral catheter technique. <i>Radiotherapy and Oncology</i> , 2007, 83, 25-30.	0.6	11
115	An image-based method to quantify biomechanical properties of the rectum in radiotherapy of prostate cancer. <i>Acta Oncologica</i> , 2015, 54, 1335-1342.	1.8	11
116	Limited post-chemotherapy retroperitoneal resection of residual tumour in non-seminomatous testicular cancer: complications, outcome and quality of life. <i>Acta Oncologica</i> , 2018, 57, 1084-1093.	1.8	11
117	Pathophysiology of late anorectal dysfunction following external beam radiotherapy for prostate cancer. <i>Acta Oncologica</i> , 2014, 53, 1398-1404.	1.8	10
118	Biology-guided adaptive radiotherapy (BiGART) is progressing towards clinical reality. <i>Acta Oncologica</i> , 2015, 54, 1245-1250.	1.8	10
119	Dummy run for a phase II study of stereotactic body radiotherapy of T1-T2 N0M0 medical inoperable non-small cell lung cancer. <i>Acta Oncologica</i> , 2006, 45, 973-977.	1.8	9
120	Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 295-301.	2.3	9
121	Plan robustness in proton beam therapy of a childhood brain tumour. <i>Acta Oncologica</i> , 2011, 50, 791-796.	1.8	9
122	Survival in patients with synchronous liver metastases in central and northern Denmark, 1998 to 2009. <i>Clinical Epidemiology</i> , 2011, 3 Suppl 1, 11.	3.0	9
123	Long-term urodynamic findings following radical prostatectomy and salvage radiotherapy. <i>Scandinavian Journal of Urology</i> , 2018, 52, 20-26.	1.0	9
124	Simulated real-time dose reconstruction for moving tumors in stereotactic liver radiotherapy. <i>Medical Physics</i> , 2019, 46, 4738-4748.	3.0	9
125	The evolution of radiotherapy techniques in the management of prostate cancer. <i>Acta Oncologica</i> , 2015, 54, 821-824.	1.8	8
126	2-[18F]fluoro-2-deoxy-d-galactose positron emission tomography guided functional treatment planning of stereotactic body radiotherapy of liver tumours. <i>Physics and Imaging in Radiation Oncology</i> , 2017, 1, 28-33.	2.9	8

#	ARTICLE	IF	CITATIONS
127	Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer. <i>Scandinavian Journal of Urology</i> , 2017, 51, 457-463.	1.0	8
128	Simulated multileaf collimator tracking for stereotactic liver radiotherapy guided by kilovoltage intrafraction monitoring: Dosimetric gain and target overdose trends. <i>Radiotherapy and Oncology</i> , 2020, 144, 93-100.	0.6	8
129	Radionecrosis and cellular changes in small volume stereotactic brain radiosurgery in a porcine model. <i>Scientific Reports</i> , 2020, 10, 16223.	3.3	8
130	A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients. <i>Acta Oncologica</i> , 2022, 61, 179-184.	1.8	8
131	Real-time dose-guidance in radiotherapy: proof of principle. <i>Radiotherapy and Oncology</i> , 2021, 164, 175-182.	0.6	8
132	Dynamic cell cycle kinetics of normal CD34+ cells and CD38+ subsets of haemopoietic progenitor cells in G-CSF-mobilized peripheral blood. <i>British Journal of Haematology</i> , 1999, 105, 1002-1013.	2.5	7
133	A phase I study on stereotactic body radiotherapy of liver metastases based on functional treatment planning using positron emission tomography with 2-[¹⁸ F]fluoro-2-deoxy-D-galactose. <i>Acta Oncologica</i> , 2017, 56, 1614-1620.	1.8	7
134	Isotoxic dose prescription level strategies for stereotactic liver radiotherapy: the price of dose uniformity. <i>Acta Oncologica</i> , 2020, 59, 558-564.	1.8	7
135	Rethink radiotherapy – BIGART 2017. <i>Acta Oncologica</i> , 2017, 56, 1341-1352.	1.8	6
136	A Nordic-Baltic perspective on indications for proton therapy with strategies for identification of proper patients. <i>Acta Oncologica</i> , 2020, 59, 1157-1163.	1.8	6
137	Risk of Cardiac Implantable Electronic Device Malfunctioning During Pencil Beam Proton Scanning in an In Vitro Setting. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 186-195.	0.8	6
138	Advances in radiotherapy: from 2D to 4D. <i>Cancer Imaging</i> , 2011, 11, S145-S152.	2.8	5
139	A biological modeling based comparison of two strategies for adaptive radiotherapy of urinary bladder cancer. <i>Acta Oncologica</i> , 2016, 55, 1009-1015.	1.8	5
140	Validation of genetic predictors of late radiation-induced morbidity in prostate cancer patients. <i>Acta Oncologica</i> , 2017, 56, 1514-1521.	1.8	5
141	Simultaneous acquisition of 4D ultrasound and wireless electromagnetic tracking for in-vivo accuracy validation. <i>Current Directions in Biomedical Engineering</i> , 2017, 3, 75-78.	0.4	5
142	Validation of fast motion-including dose reconstruction for proton scanning therapy in the liver. <i>Physics in Medicine and Biology</i> , 2018, 63, 225021.	3.0	5
143	Proton therapy for early breast cancer patients in the DBCG proton trial: planning, adaptation, and clinical experience from the first 43 patients. <i>Acta Oncologica</i> , 2022, 61, 223-230.	1.8	5
144	Uniform versus non-uniform dose prescription for proton stereotactic body radiotherapy of liver tumors investigated by extensive motion-including treatment simulations. <i>Physics in Medicine and Biology</i> , 2021, 66, 205009.	3.0	3

#	ARTICLE	IF	CITATIONS
145	198PD: Nomogram for predicting overall survival after stereotactic body radiotherapy for pulmonary metastases: Development and external validation. <i>Journal of Thoracic Oncology</i> , 2016, 11, S143.	1.1	2
146	Research in radiation oncology and the Covid-19 pandemic. <i>Acta OncolÃ³gica</i> , 2021, 60, 275-276.	1.8	2
147	Effect of stereotactic body radiotherapy on regional metabolic liver function investigated in patients by dynamic [18F]FDGal PET/CT. <i>Radiation Oncology</i> , 2021, 16, 192.	2.7	2
148	Clinical outcomes after stereotactic ablative radiotherapy in locally advanced cholangiocarcinoma. <i>Acta OncolÃ³gica</i> , 2022, 61, 197-201.	1.8	2
149	A year of pandemic for European particle radiotherapy: A survey on behalf of EPTN working group. <i>Clinical and Translational Radiation Oncology</i> , 2022, 34, 1-6.	1.7	2
150	Dynamic cell cycle kinetics in vitro and in vivo in myelodysplastic syndromes with special reference to the influence of hematopoietic growth factors. <i>Leukemia Research</i> , 2000, 24, 999-1008.	0.8	1
151	BIGART 2019 â€œ adapting to the future. <i>Acta OncolÃ³gica</i> , 2019, 58, 1323-1327.	1.8	1
152	Response to: â€œComments on â€œTemporal lobe sparing radiotherapy with photons or protons for cognitive function preservation in paediatric craniopharyngiomaâ€•by Toussaint, et al.: Prior similar field arrangement work and a need for variable RBE Useâ€™. <i>Radiation Therapy and Oncology</i> , 2021, 158, 330-331.	0.6	1
153	<i>No time to die</i>â€œ BiGART is back. The 20th Acta Oncologica Symposium â€œ BIGART 2021. <i>Acta OncolÃ³gica</i> , 2022, 61, 117-119.	1.8	1
154	Spot-scanning proton therapy for targets with adjacent cardiac implantable electronic devices â€œ Strategies for breast and head & neck cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 21, 66-71.	2.9	1
155	The effect of castration on tumour growth rate and cell kinetics in hormone-sensitive and hormone-insensitive rat prostatic adenomas. <i>Prostate Cancer and Prostatic Diseases</i> , 1999, 2, S29-S29.	3.9	0
156	Radiation Therapy for Liver Metastases: Clinical Data. , 2017, , 245-256.		0
157	Is there a Nordic solution for the â€œproton-problemâ€™?. <i>Acta OncolÃ³gica</i> , 2020, 59, 1137-1138.	1.8	0
158	Androgen Deprivation Therapy Combined With Particle Therapy for Prostate Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 695647.	2.8	0